Reporting noted all six biological-aging clock measurements moved favorably, with researcher caution that aging itself cannot be proven to have slowed.
Following·Day 3·first covered 11 Sep 2026·2 sources
Insilico Medicine's AI-designed rentosertib moves aging biomarkers in trial
The gist
The results suggest an AI-designed drug developed for one condition may have measurable effects on biological aging markers. The researchers' own caution about the limits of the analysis means the finding is preliminary.
The full picture
Insilico Medicine published clinical trial results for rentosertib, a drug originally designed by AI to treat idiopathic pulmonary fibrosis. The results showed the drug moved all six biological-aging clock measurements in a favorable direction. Researchers caution that the analysis cannot prove the drug actually slowed the aging process itself.
How it developed
Insilico Medicine published clinical trial results for rentosertib showing potential anti-aging effects.
Sources
Transformer News
The daily email
Want this in your inbox?
I send one email each morning with the stories that moved. If you would rather just read here, that works too.
Subscribe free